FAAH and inflammatory bowel disease: 5-ASA, through PPARα receptor, and glucocorticoids, through acylethenolamide producing/degrading enzymes, reduces colitis-associated inflammation suggesting PPARα agonists or FAAH/NAAA inhibitors as potential drugs for the treatment of inflammatory bowel diseases in human.